PharmaEssentia announced that it has acquired exclusive distribution rights for three rare disease injectable drugs from international pharmaceutical group Chiesi for the Taiwan and Southeast Asian markets.

The Enzyme Replacement Therapy is designed to replace specific enzymes that are deficient or absent in the patient's body to achieve a therapeutic effect," said CEO Tsai of PharmaEssentia. The three rare disease drugs are planned to be launched in Taiwan, Singapore, Malaysia, the Philippines and Vietnam, with a potential business opportunity of over $2 billion in Taiwan.

Of the three rare drugs, Revcovi is currently one of the very few treatment options for patients with severe complex immunodeficiency due to adenosine deficiency and is approved in the US and Japan. It has been licensed in the EU and some non-EU countries (including Brazil).

PRX-102, a Fabry's drug in development, is the first plant-based, chemically modified polyethylene glycolated enzyme replacement therapy with an average half-life of 80 hours, significantly longer than currently available enzyme replacement therapies.

PharmaEssentiasaid that Taiwan is the fifth market in the world to enact a special law for rare diseases, and the budget for rare diseases from 2016 to 2020 has increased from $4.5 billion to $7.7 billion, an increase of about 11%.

More informaiton please visit hq.pharmaessentia.com